Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
… review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also … Agency (EMA) and US Food & Drug Administration (FDA). RNAediting technology – accelerate development of the …
… Always excited about RNA therapies He is one of the founders of ProQR, but even … to choose RNA therapy over gene therapy or even gene editing using CRISPR-Cas, the latest hype. And the main … are still expanding our toolbox. We can now do single base RNAediting, turning a single A nucleotide into an I. It …
